SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

• R. García-Campelo ^[1] ; R. Bernabé ^[5] ; M. Cobo ^[6] ; J. Corral ^[2] ; J. Coves ^[3] ; M. Dómine ^[4] ; E. Nadal ^[7] ; D. Rodriguez-Abreu ^[8] ; N. Viñolas ^[9] ; B. Massuti ^[10]
  1. [1] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  2. [2] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  3. [3] Hospital Son Llàtzer

     Hospital Son Llàtzer

     Palma de Mallorca, España

     
  4. [4] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  5. [5] Hospital Universitario Nstra. Sra. de Valme
  6. [6] Hospital Universitario Málaga
  7. [7] Instituto Catalán de Oncología, L’Hospitalet
  8. [8] Hospital Universitario Insular de Las Palmas de Gran Canaria
  9. [9] Hospital Clinic
  10. [10] Hospital General Universitario Alicante

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 1020-1029
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87–108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al.